Company news

SIGA Technologies Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results

July 30, 2026

SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update

May 7, 2026

SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results

April 30, 2026

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2025 and Provides Business Update

March 9, 2026

SIGA to Host Business Update Call on March 10, 2026, Following Release of 2025 Financial Results

March 3, 2026

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025

November 5, 2025

SIGA to Host Business Update Call on November 6, 2025 Following Release of Third-Quarter 2025 Results

October 29, 2025

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025

August 4, 2025

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

July 28, 2025

SIGA Reports Financial Results for Three Months Ended March 31, 2025

May 7, 2025

SIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 Results

April 30, 2025

SIGA Declares Special Cash Dividend of $0.60 Per Share

April 7, 2025

SIGA Appoints Retired General John M. Keane to its Board of Directors

March 17, 2025

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2024

March 10, 2025

SIGA to Host Business Update Call on March 11, 2025 Following Release of Fourth-Quarter and Full Year 2024 Financial Results

March 3, 2025

TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses

January 1, 2025

Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced

December 9, 2024

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024

November 6, 2024

SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results

October 30, 2024

SIGA Enters into Exclusive License Agreement with Vanderbilt University for Novel Poxvirus Monoclonal Antibodies

October 21, 2024

SIGA Announces Agreement to Supply TPOXX® in Morocco

October 7, 2024

SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX®

August 20, 2024

Topline Results from PALM 007 Study of SIGA’s Tecovirimat in Treatment of Mpox Released

August 14, 2024

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2024

July 31, 2024

SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results

July 24, 2024

SIGA Announces U.S. Government Procurement Order of $113 Million for Oral TPOXX®

July 18, 2024

SIGA Announces Agreement to Sell TPOXX® to ASEAN Member States

June 16, 2024

SIGA Reports Financial Results for Three Months Ended March 31, 2024

May 6, 2024

SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results

April 30, 2024

SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX®

March 31, 2024

SIGA Names Larry Miller General Counsel

March 24, 2024

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023

March 11, 2024

SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results

March 4, 2024

SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer

January 21, 2024

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023

November 6, 2023

SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results

October 25, 2023

SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries

October 22, 2023

SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer

September 5, 2023

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2023

August 7, 2023

SIGA Technologies to Host Business Update Call on Tuesday, August 8th, 2023 Following Release of Second Quarter 2023 Financial Results

July 26, 2023

SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX®

July 26, 2023

SIGA CEO Phil Gomez, PhD, to Present on Smallpox and Orthopox Preparedness at NATO Chemical, Biological, Radiological & Nuclear Medical Symposium

June 26, 2023

SIGA Reports Financial Results for Three Months Ended March 31, 2023

May 3, 2023

SIGA Declares Special Cash Dividend of $0.45 Per Share

May 3, 2023

SIGA Technologies to Host Business Update Call on May 4th, 2023 Following Release of First Quarter 2023 Financial Results

April 26, 2023

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2022

March 1, 2023

SIGA Technologies to Host Business Update Call on March 2nd, 2023 Following Release of Fourth Quarter and Full Year 2022 Financial Results

February 22, 2023

SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023

January 16, 2023

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2022

November 2, 2022

SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results

October 26, 2022

Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks